vs
ACRES Commercial Realty Corp.（ACR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是ACRES Commercial Realty Corp.的1.5倍（$30.3M vs $20.0M），ACRES Commercial Realty Corp.净利率更高（31.6% vs -221.3%，领先253.0%），REGENXBIO Inc.同比增速更快（43.0% vs -6.5%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 3.3%）
皮拉马尔地产是一家印度房地产企业，2012年成立，总部位于印度孟买，隶属于皮拉马尔集团。公司专注于住宅及商业地产开发，目前在手开发项目总规模约达1500万平方英尺，知名项目包括Piramal Aranya、Piramal Mahalaxmi等。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ACR vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.5倍
$20.0M
营收增速更快
RGNX
高出49.5%
-6.5%
净利率更高
ACR
高出253.0%
-221.3%
两年增速更快
RGNX
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.0M | $30.3M |
| 净利润 | $6.3M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 30.8% | -190.0% |
| 净利率 | 31.6% | -221.3% |
| 营收同比 | -6.5% | 43.0% |
| 净利润同比 | -32.0% | -31.2% |
| 每股收益（稀释后） | $-0.41 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACRRGNX
| Q4 25 | $20.0M | $30.3M | ||
| Q3 25 | $21.0M | $29.7M | ||
| Q2 25 | $21.9M | $21.4M | ||
| Q1 25 | $17.0M | $89.0M | ||
| Q4 24 | $21.4M | $21.2M | ||
| Q3 24 | $22.4M | $24.2M | ||
| Q2 24 | $20.9M | $22.3M | ||
| Q1 24 | $18.8M | $15.6M |
净利润ACRRGNX
| Q4 25 | $6.3M | $-67.1M | ||
| Q3 25 | $18.0M | $-61.9M | ||
| Q2 25 | $4.3M | $-70.9M | ||
| Q1 25 | $-730.0K | $6.1M | ||
| Q4 24 | $9.3M | $-51.2M | ||
| Q3 24 | $8.1M | $-59.6M | ||
| Q2 24 | $6.4M | $-53.0M | ||
| Q1 24 | $4.9M | $-63.3M |
毛利率ACRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率ACRRGNX
| Q4 25 | 30.8% | -190.0% | ||
| Q3 25 | 85.8% | -176.3% | ||
| Q2 25 | 19.8% | -296.3% | ||
| Q1 25 | -3.8% | 13.6% | ||
| Q4 24 | 43.4% | -242.1% | ||
| Q3 24 | 36.4% | -256.6% | ||
| Q2 24 | 30.8% | -251.3% | ||
| Q1 24 | 26.2% | -408.8% |
净利率ACRRGNX
| Q4 25 | 31.6% | -221.3% | ||
| Q3 25 | 85.8% | -208.3% | ||
| Q2 25 | 19.8% | -331.8% | ||
| Q1 25 | -4.3% | 6.8% | ||
| Q4 24 | 43.5% | -241.3% | ||
| Q3 24 | 36.0% | -246.3% | ||
| Q2 24 | 30.6% | -237.7% | ||
| Q1 24 | 26.2% | -405.4% |
每股收益（稀释后）ACRRGNX
| Q4 25 | $-0.41 | $-1.30 | ||
| Q3 25 | $1.34 | $-1.20 | ||
| Q2 25 | $-0.10 | $-1.38 | ||
| Q1 25 | $-0.80 | $0.12 | ||
| Q4 24 | $0.51 | $-0.99 | ||
| Q3 24 | $0.36 | $-1.17 | ||
| Q2 24 | $0.21 | $-1.05 | ||
| Q1 24 | $0.07 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $83.8M | $230.1M |
| 总债务越低越好 | $1.6B | — |
| 股东权益账面价值 | $420.8M | $102.7M |
| 总资产 | $2.2B | $453.0M |
| 负债/权益比越低杠杆越低 | 3.68× | — |
8季度趋势，按日历期对齐
现金及短期投资ACRRGNX
| Q4 25 | $83.8M | $230.1M | ||
| Q3 25 | $40.9M | $274.2M | ||
| Q2 25 | $42.7M | $323.3M | ||
| Q1 25 | $66.0M | $267.9M | ||
| Q4 24 | $56.7M | $234.7M | ||
| Q3 24 | $70.1M | $255.5M | ||
| Q2 24 | $89.6M | $290.4M | ||
| Q1 24 | $84.6M | $338.7M |
总债务ACRRGNX
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.6B | — |
股东权益ACRRGNX
| Q4 25 | $420.8M | $102.7M | ||
| Q3 25 | $432.9M | $161.5M | ||
| Q2 25 | $425.3M | $213.7M | ||
| Q1 25 | $430.1M | $274.2M | ||
| Q4 24 | $439.1M | $259.7M | ||
| Q3 24 | $436.3M | $301.4M | ||
| Q2 24 | $434.0M | $348.3M | ||
| Q1 24 | $432.8M | $390.7M |
总资产ACRRGNX
| Q4 25 | $2.2B | $453.0M | ||
| Q3 25 | $1.7B | $525.2M | ||
| Q2 25 | $1.8B | $581.0M | ||
| Q1 25 | $1.8B | $490.9M | ||
| Q4 24 | $1.9B | $466.0M | ||
| Q3 24 | $2.0B | $519.1M | ||
| Q2 24 | $2.1B | $569.4M | ||
| Q1 24 | $2.1B | $629.2M |
负债/权益比ACRRGNX
| Q4 25 | 3.68× | — | ||
| Q3 25 | 2.76× | — | ||
| Q2 25 | 3.10× | — | ||
| Q1 25 | 2.97× | — | ||
| Q4 24 | 3.12× | — | ||
| Q3 24 | 3.43× | — | ||
| Q2 24 | 3.67× | — | ||
| Q1 24 | 3.79× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 0.65× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ACRRGNX
| Q4 25 | $4.1M | $-52.3M | ||
| Q3 25 | $-9.4M | $-56.0M | ||
| Q2 25 | $11.8M | $-49.3M | ||
| Q1 25 | $-4.6M | $33.6M | ||
| Q4 24 | $19.4M | $-31.6M | ||
| Q3 24 | $8.4M | $-40.5M | ||
| Q2 24 | $6.9M | $-45.5M | ||
| Q1 24 | $3.3M | $-55.5M |
自由现金流ACRRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率ACRRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度ACRRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率ACRRGNX
| Q4 25 | 0.65× | — | ||
| Q3 25 | -0.52× | — | ||
| Q2 25 | 2.72× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 2.08× | — | ||
| Q3 24 | 1.05× | — | ||
| Q2 24 | 1.07× | — | ||
| Q1 24 | 0.68× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACR
| Other | $10.8M | 54% |
| Pacmulti JVLLC | $5.2M | 26% |
| Mccallum Jv Llc | $2.5M | 12% |
| Office Complex | $1.5M | 7% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
